GlassScriptPhysician profile
Eric J Meinhardt
NPI 1033436654
$9,883.95
in general payments reported to CMS, 2019-2025
32 companies · $3,769 in 2025
The $3,769 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2021: $265 · 2022: $823 · 2023: $1,653 · 2024: $3,150 · 2025: $3,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,478 · Education: $93.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,478.06 |
| Education | $93.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.86 | 2022-2025 | |
| Genzyme Corporation | $1,072.07 | 2021-2025 | |
| Janssen Biotech, INC. | $925.63 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $910.25 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $740.49 | 2019-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $570.78 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $555.73 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $475.07 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $461.81 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $437.36 | 2019-2025 | Dysport, Aklief, Nemluvio |
| Incyte Corporation | $374.83 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $332.46 | 2023-2024 | Vtama |
| Merz North America, INC. | $198.91 | 2022-2025 | Xeomin |
| Leo Pharma INC. | $195.89 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $191.32 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $135.53 | 2025 | Daxxify |
| Journey Medical Corporation | $82.43 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $78.84 | 2021-2024 | |
| Kyowa Kirin, INC. | $74.76 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.30 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Allergan, INC. | $69.58 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $58.80 | 2023-2025 | Ycanth |
| Botanix Sb INC | $53.01 | 2025 | Sofdra |
| Organon LLC | $50.53 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $48.94 | 2024 | Xtrac |
| Organogenesis INC. | $38.77 | 2023 | Puraply |
| Mindera Corp | $35.61 | 2025 | |
| Almirall LLC | $35.41 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $24.28 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.29 | 2023 | Spevigo |
| Epi Health, LLC | $18.17 | 2019 | |
| Genentech USA, INC. | $16.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Meinhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.